Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @FPrimeCapital
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @FPrimeCapital
-
F-Prime Capital proslijedio/la je Tweet
The lab-software stack is changing. Here's howhttp://bit.ly/2uihSzm
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thrilled to announce our investment in
@BenchSci! Leveraging AI to help biomedical scientists cut time and costs from research.
http://ow.ly/NQo550yd651 Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our tech team did an end-of-year reflection on the current state of venture. We are sharing it with our broader community in the hope that someone will find it informative, interesting or at least entertaining.http://bit.ly/2UcNdhs
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today’s
@WashingtonPost highlights a pressing issue – the gender imbalance in the biotech industry. F-Prime is committed to supporting efforts to increase the number of women in leadership positions.https://www.washingtonpost.com/science/2020/01/29/bias-biotech-funding-has-blocked-women-led-companies/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
F-Prime Capital proslijedio/la je Tweet
So excited to host Jeremy Allaire at our next Founders Diaries. A true rock star founder who has redefined multiple industries
@circlepay@Brightcove Macromedia@jerallaire@FPrimeCapitalhttps://twitter.com/redphase/status/1219712541535940610 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Excited to announce our investment in
@funnel with our sister fund@8roadsventures.https://techcrunch.com/2020/01/16/funnel-series-b/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congratulations to portfolio company
@OvivaHealth for successfully raising $21M Series B to roll out digital diabetes treatment across Europe#digitalhealth#HealthTechhttps://techcrunch.com/2020/01/14/oviva/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Awesome news for
@Plaid (and the team of acquired@quovo) on their impressive acquisition by@Visa. Huge step forward for FinTech infrastructure!http://ow.ly/Cekr50xV9T7Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Yesterday was a very big day for our portfolio company
@LumereHQ. We’re proud to support you!https://twitter.com/LumereHQ/status/1216789182443593728 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Very proud of our portfolio company
@PrecisionBioSci for reaching this important milestone! Congrats to the team.https://twitter.com/PrecisionBioSci/status/1216750967875653632 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Don’t miss the latest news from
@ApellisPharma, in@statnews – the company’s drug candidate for a rare blood condition outperformed a blockbuster drug in a clinical trial comparing the two:https://www.statnews.com/2020/01/07/new-data-apellis-pharmaceuticals/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sending our congrats to the fantastic team at Turnstone Biologics on their new strategic collaboration with Takeda to develop multiple products using their viral immunotherapy platform.https://twitter.com/FierceBiotech/status/1207674633064976384 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thrilled to share our portfolio company
@CarebyFirefly, announced a new partnership with PhysicianOne Urgent Care to provide more convenient options for to patients. Congrats to the team! Learn more: https://www.firefly.health/post/firefly-health-and-physicianone-urgent-care-partnership …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
F-Prime Capital proslijedio/la je Tweet
Great write up in
@Forbes from@johncumbers today on how#technology will be crucial in enabling the next wave of life science breakthroughs and what@sajithw and@benchling are building to unlock the potential of big#data in#biologyhttps://twitter.com/SynBioBeta/status/1207722284141752322 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
F-Prime Capital proslijedio/la je Tweet
Great write up in
@Forbes from@johncumbers today on how#technology will be crucial in enabling the next wave of life science breakthroughs and what@benchling@sajithw is building to unlock the potential of big#data in#biologyhttps://www.forbes.com/sites/johncumbers/2019/12/19/how-the-cloud-can-solve-life-sciences-big-data-problem/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
F-Prime Capital proslijedio/la je Tweet
We've appointed
#healthcare industry veteran and serial#entrepreneur Michael Heffernan as Indalo's Board Chair -https://indalotherapeutics.com/2019/12/17/indalo-therapeutics-appoints-healthcare-industry-veteran-and-serial-entrepreneur-michael-heffernan-as-board-chair/ …#drugdevelopment#liverdisease#biotech#NASH#IPFHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
F-Prime Capital proslijedio/la je Tweet
I can check an item off the bucket list.
@TheEllenShow has promoted an@FPrimeCapital company product. Congrats@embarkvet for making Ellen’s#12days list, presented by@blakeshelton no less!https://twitter.com/TheEllenShow/status/1205546237711118337 …
6:13Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
F-Prime Capital proslijedio/la je Tweet
Case study on
@benchling@sajithw@daashu - https://axial.substack.com/p/axial-benchling …@ericvishria@benchmark@MenloVentures@mmurph@grgyap@a16z@vijaypande@balajis@JorgeCondeBio@ycombinator@Rock_Health@ThriveCapital@milesgrimshaw@FPrimeCapitalpic.twitter.com/vzgoNHxl6V
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Innovent Biologics hit yet another significant milestone this week with the dosing of the first patient in its Phase 1 clinical trial of its anti-tumor therapy IBI110:https://www.prnewswire.com/news-releases/innovent-announces-first-patient-dosed-in-phase-i-clinical-trial-of-anti-lag-3-monoclonal-antibody-in-china-300969948.html …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congratulations to the impressive team at portfolio company
@Adaptimmune. The@US_FDA has granted RMAT designation to ADP‑A2M4 for the treatment of synovial sarcoma.https://twitter.com/Adaptimmune/status/1202265247547035649 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.